Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results1 for the year ending December 31, 2022. The consolidated financial statements are attached to this press release. “In 2022 we made important progress in our pipeline, both on our clinical and preclinical projects as well as maintaining a strong financial position.

Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022.

Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) has learned that Silicon Valley Bank has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. None of Innate Pharma's cash and cash equivalents are held through Silicon Valley Bank and none of its investment portfolio has exposure to Silicon Valley Bank.

Innate Pharma Provides Update on Silicon Valley Bank Exposure

MARSEILLE, France--( BUSINESS WIRE )--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi. The licensing agreement is now effective.

Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers

MARSEILLE, France--( BUSINESS WIRE )--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. The studies were conducted by Innate and Sanofi and published in Nature Biotechnology on January 12, 2023.

Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

AGM Group Holdings Inc - Ordinary Shares - Class A

Assembly Biosciences

Ensysce Biosciences

LianBio

Soleno Therapeutics

Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 6 To Watch With Big News Today

Sanofi

Shares of Innate Pharma SA ADR [S: ipha] rallied 35.2% in premarket trading on Monday after the company said Sanofi SNY, -0.38% licensed its natural killer (NK) cell engager program as part of an already established collaboration between the two companies. "We are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy," Valeria Fantin, Sanofi's global head of oncology research, said in a news release.

Innate, Sanofi ink licensing deal for NK cells

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

MARSEILLE, France--( BUSINESS WIRE )--Regulatory News:

Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

Innate Pharma S.A. (NASDAQ:IPHA ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Henry Wheeler – Head-Investor Relations Mondher Mahjoubi – Chief Executive Officer Joyson Karakunnel – Executive Vice President and Chief Medical Officer Yannis Morel – Executive Vice President-Business Development and Product Portfolio Strategy Conference Call Participants Yigal Nochomovitz – Citigroup Daina Graybosch – SVB Securities Swayampakula Ramakanth – HCW Operator Hello, and thank you for standing by.

Innate Pharma S.A. (IPHA) Q3 2022 Earnings Call Transcript

Innate Pharma Reports Third Quarter Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for third quarter 2022 business update

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the 64th ASH (American Society Hematology) Annual Meeting taking place from December 10-13, 2022, in New Orleans, Louisiana.

Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma 2023 financial calendar

Innate Pharma 2023 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that lacutamab, an anti-KIR3DL2 antibody, demonstrated clinical responses in patients with mycosis fungoides (MF), in the ongoing Phase 2 TELLOMAK clinical trial. The results will be shared in an oral presentation at the EORTC CLTG1 Annual Meeting, taking place from 22-24 September 2022 in Madrid, Spain, presented by Pr. Martine Bagot, Head of the

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma S.A. (NASDAQ:IPHA ) First Half 2022 Financial Results and Business Update September 15, 2022 8:00 AM ET Company Participants Henry Wheeler – Investor Relations Mondher Mahjoubi – Chief Executive Officer Joyson Karakunnel – Executive Vice President and Chief Medical Officer Yannis Morel – Executive Vice President-Business Development and Product Portfolio Strategy Frédéric Lombard – Chief Financial Officer Conference Call Participants Carly Kenselaar – Citi Daina Graybosch – SVB Securities Nick Hallatt – Goldman Sachs Olga Smolentseva – Bryan Garnier Henry Wheeler Good morning and good afternoon and welcome everybody.

Innate Pharma S.A. (IPHA) First Half 2022 Financial Results and Business Update Transcript

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports first half 2022 financial results and business update

Innate Pharma Reports First Half 2022 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for first half 2022 business update

Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the ESMO (European Society for Medical Oncology) Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. A multi-center Phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2 - A

Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

The stock price of Innate Pharma (IPHA) fell by over 7% during intraday trading today. This is why.

Innate Pharma (IPHA) Stock: Why It Fell Over 7% Today

AstraZeneca

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca (LSE/STO/Nasdaq: AZN) did not meet a pre-defined threshold for efficacy. Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued. There were no new

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision to progress IPH6401/SAR'514 into investigational new drug (IND)-enabling studies, triggering a €3 million milestone payment. IPH6401/SAR'514 is a BCMA-targeting NK cell engager using Sanofi's proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format. It in

Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces IPH5201 Phase 2 study in lung cancer

News for Innate Pharma SA Stock (IPHA)